{"SPADE_UN_15648": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_15648", "Peptide Name": "HS5", "Source": "Synthetic", "Family": "", "Gene": "Not found", "Sequence": "GAISLAPKLQINE", "Sequence Length": 13, "UniProt Entry": ["http://www.uniprot.org/uniprot/Notavailable"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Anticancer"], "Target Organism": "Tumor cells:CT26 (IC50=1.56±0.35 µM)", "Hemolytic Activity": "Not available", "Cytotoxicity": "Not available", "Binding Target": "programmed cell death protein 1", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "Mix", "Structure Description": "Not found", "Formula": "C55H95N15O15", "Mass": 1353.56, "PI": 6.22, "Net Charge": 0, "Hydrophobicity": 0.23, "Half Life": "Mammalian:30 hourYeast:>20 hourE.coli:>10 hour", "Literature": [{"Title": "Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy", "Pubmed ID": "33360579", "Reference": "Bioorg Med Chem. 2021 Jan 15;30115951.", "Author": "Orafaie A, Sadeghian H, Bahrami AR, Rafatpanah H, Matin MM.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=33360579"}], "Frequent Amino Acids": "AIL", "Absent Amino Acids": "CDFHMORTUVWY", "Basic Residues": 1, "Acidic Residues": 1, "Hydrophobic Residues": 7, "Polar Residues": 6, "Positive Residues": 1, "Negative Residues": 1, "Similar Sequences": [{"SPADE_ID": "SPADE_N_08434", "Similarity": 1.0, "Sequence": "KKIGAIKKWGAIKKIGAI"}, {"SPADE_ID": "SPADE_UN_15642", "Similarity": 1.0, "Sequence": "CGAISLAKLQINES"}, {"SPADE_ID": "SPADE_UN_15646", "Similarity": 1.0, "Sequence": "GAISLAKLQINEG"}]}}}